AACHEN, Germany--(BUSINESS WIRE)--Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of ...

SANTA ROSA, Calif.--(BUSINESS WIRE)--Claret Medical® today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Sentinel™ Cerebral Protection ...

SENTINEL trial to evaluate the Safety and Efficacy of the Sentinel CPS in TAVR population SANTA ROSA, CA. -- Claret Medical, Inc., a developer of innovative solutions for cerebral protection during ...

Please provide your email address to receive an email when new articles are posted on . Adults who underwent transcatheter aortic valve replacement with a cerebral protection system experienced fewer ...

MARLBOROUGH, Mass., Sept. 17, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced results from the PROTECTED TAVR clinical trial evaluating the SENTINEL™ Cerebral Protection ...

Background: Stroke associated with transcatheter aortic valve replacement (TAVR) is a potentially devastating complication. Until recently, the Sentinel™ Cerebral Protection System (CPS; Boston ...

The Sentinel cerebral protection system (Boston Scientific) was infrequently used during TAVI procedures performed in Germany over a recent 3-year span, and it was not associated with less clinical ...

SANTA CRUZ, Calif., Sept. 9, 2026 /PRNewswire/ -- Emboline, Inc., a medical technology company developing next-generation embolic protection technology, today announced that the U.S. Food and Drug ...

High-risk surgical patients in community hospital settings can safely benefit from the use of new embolus-removing and stent-inserting systems, according to a study presented today at the American ...

Please provide your email address to receive an email when new articles are posted on . The device (TriGuard 3, Keystone Heart) showed potential to prevent larger ischemic brain lesions, Jeffrey W.

The FDA's decision follows a clinical assessment of the Emboliner, including the PROTECT H2H IDE study.